Study identifier:D8455R00001
ClinicalTrials.gov identifier:NCT07690436
EudraCT identifier:N/A
CTIS identifier:N/A
A Multicenter Pilot Study to Investigate Ocular Involvement and the Potential of Ocular Imaging for Non-invasive Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin Amyloid Cardiomyopathy
-
no
-
All
500
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jul 2026 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions |
|---|---|
| ATTR-CM Participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). | - |
| HF Control Participants with guideline-directed medical therapy-directed heart failure and documentation within the past 2 years that either excludes transthyretin amyloid cardiomyopathy (ATTR-CM) or indicates a low probability of ATTR-CM. | - |